Theravance Biopharma, Inc. Increase Decrease In Operating Lease Liability
Theravance Biopharma, Inc. (TBPH) reported Increase Decrease In Operating Lease Liability of -$4.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- Theravance Biopharma, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.94M.
- Theravance Biopharma, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$2.20M.
- Theravance Biopharma, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.89M, a 139.10% decline year-over-year.
- Theravance Biopharma, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.86M.
- Theravance Biopharma, Inc. increase decrease in operating lease liability for fiscal 2025 was -$7.12M, a 1176.70% decline from fiscal 2024.
- Theravance Biopharma, Inc. increase decrease in operating lease liability for fiscal 2024 was $661.00K.
- Theravance Biopharma, Inc. increase decrease in operating lease liability for fiscal 2023 was -$3.00M.
- Theravance Biopharma, Inc. increase decrease in operating lease liability for fiscal 2022 was -$1.02M.
| Period end | Increase Decrease In Operating Lease Liability 1 month | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.13M 10-Q · filed 2026-08-11 | -$6.03M derived: sum of 3 quarters · filed 2026-08-11 | -$7.89M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$2.20M 10-Q · filed 2026-05-07 | -$4.09M derived: sum of 2 quarters · filed 2026-05-07 | -$5.95M derived: sum of 3 quarters · filed 2026-05-07 | -$7.65M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$3.75M derived: sum of 2 quarters · filed 2026-03-23 | -$5.45M derived: sum of 3 quarters · filed 2026-08-11 | -$7.12M 10-K · filed 2026-03-23 | |
| 2025-09-30 | -$1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$3.56M derived: sum of 2 quarters · filed 2026-08-11 | -$5.22M 10-Q · filed 2025-11-12 | -$386.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$3.36M 10-Q · filed 2026-08-11 | $1.48M derived: sum of 3 quarters · filed 2026-08-11 | -$204.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$1.66M 10-Q · filed 2026-05-07 | $3.17M derived: sum of 2 quarters · filed 2026-05-07 | $1.50M derived: sum of 3 quarters · filed 2026-05-07 | $253.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.16M derived: sum of 2 quarters · filed 2026-03-23 | $1.92M derived: sum of 3 quarters · filed 2026-03-23 | $661.00K 10-K · filed 2026-03-23 | |
| 2024-09-30 | -$1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.92M derived: sum of 2 quarters · filed 2025-11-12 | -$4.18M 10-Q · filed 2025-11-12 | -$5.85M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$2.50M 10-Q · filed 2025-08-13 | -$4.17M derived: sum of 3 quarters · filed 2025-08-13 | -$5.02M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$1.26M 10-Q · filed 2025-05-12 | -$2.93M derived: sum of 2 quarters · filed 2025-05-12 | -$3.78M derived: sum of 3 quarters · filed 2025-05-12 | -$3.29M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$2.52M derived: sum of 2 quarters · filed 2025-03-07 | -$2.04M derived: sum of 3 quarters · filed 2025-03-07 | -$3.00M 10-K · filed 2025-03-07 | |
| 2023-09-30 | -$850.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$363.00K derived: sum of 2 quarters · filed 2024-11-14 | -$1.33M 10-Q · filed 2024-11-14 | -$1.24M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $487.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$479.00K 10-Q · filed 2024-08-08 | -$392.00K derived: sum of 3 quarters · filed 2024-08-08 | -$1.58M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$966.00K 10-Q · filed 2024-05-15 | -$879.00K derived: sum of 2 quarters · filed 2024-05-15 | -$2.07M derived: sum of 3 quarters · filed 2024-05-15 | -$275.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$1.11M derived: sum of 2 quarters · filed 2024-03-01 | $691.00K derived: sum of 3 quarters · filed 2024-03-01 | -$1.02M 10-K · filed 2024-03-01 | |
| 2022-09-30 | -$1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $604.00K derived: sum of 2 quarters · filed 2023-11-09 | -$1.11M 10-Q · filed 2023-11-09 | -$3.30M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $82.00K 10-Q · filed 2023-08-09 | -$2.10M derived: sum of 3 quarters · filed 2023-08-09 | -$3.38M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | -$1.72M 10-Q · filed 2023-05-10 | -$3.90M derived: sum of 2 quarters · filed 2023-05-10 | -$5.17M derived: sum of 3 quarters · filed 2023-05-10 | -$4.62M derived: sum of 4 quarters · filed 2023-05-10 | |
| 2021-12-31 | -$2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$3.46M derived: sum of 2 quarters · filed 2023-03-01 | -$2.90M derived: sum of 3 quarters · filed 2023-03-01 | -$1.74M 10-K · filed 2023-03-01 | |
| 2021-09-30 | -$1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$716.00K derived: sum of 2 quarters · filed 2022-11-09 | $443.00K 10-Q · filed 2022-11-09 | $22.00K derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-07-31 | -$3.00M 10-K · filed 2022-02-28 | ||||
| 2021-06-30 | $559.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.72M 10-Q · filed 2022-08-08 | $1.30M derived: sum of 3 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $1.16M 10-Q · filed 2022-05-06 | $738.00K derived: sum of 2 quarters · filed 2023-03-01 | |||
| 2020-12-31 | -$421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.60M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $2.02M 10-Q · filed 2021-11-08 | ||||
| 2019-12-31 | -$2.32M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |